Paul Negulescu
Seminars
Wednesday 27th January 2027
One Year of JOURNAVX in Practice: Emerging Real-World Insights from the First Approved NaV1.8 Pain Therapy
9:00 am
- Review recently published real-world and Phase IV evidence evaluating JOURNAVX use in clinical practice
- Examine emerging data on opioid-sparing outcomes and the evolving role of non-opioid therapies in acute pain management
- Explore prescribing patterns and treatment utilization trends from the growing body of post-launch evidence
- Discuss key considerations for advancing future pain therapies, including remaining challenges around efficacy, access, reimbursement, and demonstrating value beyond opioids
Wednesday 27th January 2027
Panel Discussion: Is NaV1.8 the Silver Bullet for Pain, or Does Clinical Success Depend on Matching Mechanism to Pain Biology?
9:30 am
- Is pain better viewed as a collection of biologically distinct diseases?
- Which pain phenotypes are most likely to benefit from NaV1.8 inhibition?
- Where might alternative mechanisms out perform sodium channel blockade?
- Why do promising assets continue to fail despite compelling target biology?
- How should developers match mechanism, indication and patient population to improve clinical success?
Wednesday 27th January 2027
Panel Discussion: Solving the Placebo Problem in Chronic Pain Trials
3:30 pm
- Reduce placebo inflation through protocol design and site management
- Improve patient training and consistency across sites
- Examine crossover and adaptive study designs
- Apply lessons from successful recent programs
